Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma

Joydeep Mukherjee, Tor Christian Johannessen, Shigeo Oba, Tracy T. Chow, Lindsey Jones, Ajay Pandita, Russell O. Pieper

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A subset of tumors use a recombination-based alternative lengthening of telomere (ALT) pathway to resolve telomeric dysfunction in the absence of TERT. Loss-of-function mutations in the chromatin remodeling factor ATRX are associated with ALT but are insufficient to drive the process. Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis. In p53/pRb–deficient human astrocytes, combined deletion of ATRX and expression of mutant IDH1 were sufficient to create tumorigenic cells with ALT characteristics. The telomere capping complex component RAP1 and the nonhomologous DNA end joining repair factor XRCC1 were each downregulated consistently in these tumorigenic cells, where their coordinate reexpression was sufficient to suppress the ALT phenotype. RAP1 or XRCC1 downregulation cooperated with ATRX loss in driving the ALT phenotype. RAP1 silencing caused telomere dysfunction in ATRX-deficient cells, whereas XRCC1 silencing suppressed lethal fusion of dysfunctional telomeres by allowing IDH1-mutant ATRX-deficient cells to use homologous recombination and ALT to resolve telomeric dysfunction and escape cell death. Overall, our studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis. Significance: Studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis and suggesting new therapeutic options to treat low-grade gliomas.

Original languageEnglish
Pages (from-to)2966-2977
Number of pages12
JournalCancer Research
Volume78
Issue number11
DOIs
Publication statusPublished - 01-06-2018

Fingerprint

Telomere Homeostasis
Glioma
Telomere
Phenotype
DNA End-Joining Repair
DNA Repair
Down-Regulation
Isocitrate Dehydrogenase
Chromatin Assembly and Disassembly
Homologous Recombination
Astrocytoma
Glioblastoma
Astrocytes
Genetic Recombination
Neoplasms
Cell Death
Mutation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mukherjee, J., Johannessen, T. C., Oba, S., Chow, T. T., Jones, L., Pandita, A., & Pieper, R. O. (2018). Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma. Cancer Research, 78(11), 2966-2977. https://doi.org/10.1158/0008-5472.CAN-17-2269
Mukherjee, Joydeep ; Johannessen, Tor Christian ; Oba, Shigeo ; Chow, Tracy T. ; Jones, Lindsey ; Pandita, Ajay ; Pieper, Russell O. / Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma. In: Cancer Research. 2018 ; Vol. 78, No. 11. pp. 2966-2977.
@article{d23413e42ccb4dd997f2110910235cac,
title = "Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma",
abstract = "A subset of tumors use a recombination-based alternative lengthening of telomere (ALT) pathway to resolve telomeric dysfunction in the absence of TERT. Loss-of-function mutations in the chromatin remodeling factor ATRX are associated with ALT but are insufficient to drive the process. Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis. In p53/pRb–deficient human astrocytes, combined deletion of ATRX and expression of mutant IDH1 were sufficient to create tumorigenic cells with ALT characteristics. The telomere capping complex component RAP1 and the nonhomologous DNA end joining repair factor XRCC1 were each downregulated consistently in these tumorigenic cells, where their coordinate reexpression was sufficient to suppress the ALT phenotype. RAP1 or XRCC1 downregulation cooperated with ATRX loss in driving the ALT phenotype. RAP1 silencing caused telomere dysfunction in ATRX-deficient cells, whereas XRCC1 silencing suppressed lethal fusion of dysfunctional telomeres by allowing IDH1-mutant ATRX-deficient cells to use homologous recombination and ALT to resolve telomeric dysfunction and escape cell death. Overall, our studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis. Significance: Studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis and suggesting new therapeutic options to treat low-grade gliomas.",
author = "Joydeep Mukherjee and Johannessen, {Tor Christian} and Shigeo Oba and Chow, {Tracy T.} and Lindsey Jones and Ajay Pandita and Pieper, {Russell O.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-17-2269",
language = "English",
volume = "78",
pages = "2966--2977",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

Mukherjee, J, Johannessen, TC, Oba, S, Chow, TT, Jones, L, Pandita, A & Pieper, RO 2018, 'Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma', Cancer Research, vol. 78, no. 11, pp. 2966-2977. https://doi.org/10.1158/0008-5472.CAN-17-2269

Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma. / Mukherjee, Joydeep; Johannessen, Tor Christian; Oba, Shigeo; Chow, Tracy T.; Jones, Lindsey; Pandita, Ajay; Pieper, Russell O.

In: Cancer Research, Vol. 78, No. 11, 01.06.2018, p. 2966-2977.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma

AU - Mukherjee, Joydeep

AU - Johannessen, Tor Christian

AU - Oba, Shigeo

AU - Chow, Tracy T.

AU - Jones, Lindsey

AU - Pandita, Ajay

AU - Pieper, Russell O.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - A subset of tumors use a recombination-based alternative lengthening of telomere (ALT) pathway to resolve telomeric dysfunction in the absence of TERT. Loss-of-function mutations in the chromatin remodeling factor ATRX are associated with ALT but are insufficient to drive the process. Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis. In p53/pRb–deficient human astrocytes, combined deletion of ATRX and expression of mutant IDH1 were sufficient to create tumorigenic cells with ALT characteristics. The telomere capping complex component RAP1 and the nonhomologous DNA end joining repair factor XRCC1 were each downregulated consistently in these tumorigenic cells, where their coordinate reexpression was sufficient to suppress the ALT phenotype. RAP1 or XRCC1 downregulation cooperated with ATRX loss in driving the ALT phenotype. RAP1 silencing caused telomere dysfunction in ATRX-deficient cells, whereas XRCC1 silencing suppressed lethal fusion of dysfunctional telomeres by allowing IDH1-mutant ATRX-deficient cells to use homologous recombination and ALT to resolve telomeric dysfunction and escape cell death. Overall, our studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis. Significance: Studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis and suggesting new therapeutic options to treat low-grade gliomas.

AB - A subset of tumors use a recombination-based alternative lengthening of telomere (ALT) pathway to resolve telomeric dysfunction in the absence of TERT. Loss-of-function mutations in the chromatin remodeling factor ATRX are associated with ALT but are insufficient to drive the process. Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis. In p53/pRb–deficient human astrocytes, combined deletion of ATRX and expression of mutant IDH1 were sufficient to create tumorigenic cells with ALT characteristics. The telomere capping complex component RAP1 and the nonhomologous DNA end joining repair factor XRCC1 were each downregulated consistently in these tumorigenic cells, where their coordinate reexpression was sufficient to suppress the ALT phenotype. RAP1 or XRCC1 downregulation cooperated with ATRX loss in driving the ALT phenotype. RAP1 silencing caused telomere dysfunction in ATRX-deficient cells, whereas XRCC1 silencing suppressed lethal fusion of dysfunctional telomeres by allowing IDH1-mutant ATRX-deficient cells to use homologous recombination and ALT to resolve telomeric dysfunction and escape cell death. Overall, our studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis. Significance: Studies show how expression of mutant IDH1 initiates telomeric dysfunction and alters DNA repair pathway preferences at telomeres, cooperating with ATRX loss to defeat a key barrier to gliomagenesis and suggesting new therapeutic options to treat low-grade gliomas.

UR - http://www.scopus.com/inward/record.url?scp=85045213158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045213158&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-2269

DO - 10.1158/0008-5472.CAN-17-2269

M3 - Article

AN - SCOPUS:85045213158

VL - 78

SP - 2966

EP - 2977

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -